Results 41 to 50 of about 18,936 (261)

Assessing suicidal risk with antiepileptic drugs

, 2010
Marco Mula2, Gail S Bell1, Josemir W Sander1,31Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, and National Hospital for Neurology and Neurosurgery, UCL Hospitals NHS Foundation Trust, London, United Kingdom; 2Department of ...
Sander, JW, Marco Mula, Josemir W Sander, Bell, GS, Mula, M, Gail S Bell   +5 more
core   +1 more source

Evaluation of orally disintegrating tablets: regulatory pathways, administration practices and harmonization of bioequivalence study design

AAPS Open
Orally disintegrating tablets (ODTs) are a solid oral dosage form designed to rapidly disintegrate in the mouth without the need for water, improving patient compliance—particularly among pediatric, geriatric, and dysphagic populations.
Shapali Bagde, Xinyuan Xi, Heather Boyce, Myong-Jin Kim   +3 more
doaj   +1 more source

Effect of Antioxidants in Medicinal Products on Intestinal Drug Transporters

Pharmaceutics
The presence of mutagenic and carcinogenic N-nitrosamine impurities in medicinal products poses a safety risk. While incorporating antioxidants in formulations is a potential mitigation strategy, concerns arise regarding their interference with drug ...
Chetan P. Kulkarni, Jia Yang, Megan L. Koleske, Giovanni Lara, Khondoker Alam, Andre Raw, Bhagwant Rege, Liang Zhao, Dongmei Lu, Lei Zhang, Lawrence X. Yu, Robert A. Lionberger, Kathleen M. Giacomini, Deanna L. Kroetz, Sook Wah Yee   +14 more
doaj   +1 more source

Overview of drugs approved by the FDA in 2022

Фармация и фармакология (Пятигорск), 2023
The aim of the work is to conduct a review of medications approved by the FDA in 2022.Materials and methods. In searching for the materials to write this review article, bibliographic databases including PubMed, Google Scholar and e-library.ru were ...
D. V. Kurkin, E. I. Morkovin, D. A. Bakulin, Yu. V. Gorbunova, Yu. A. Kolosov, M. A. Dzhavakhyan, I. E. Makarenko, R. V. Drai, A. V. Zaborovsky, O. V. Shatalova, A. V. Strygin, V. I. Petrov, A. P. Pleten, A. A. Prokopov, T. Yu. Tatarenko-Kozmina   +14 more
doaj   +1 more source

Health‐Related Quality of Life and Symptom Severity Among Patients With PIK3CA‐Related Overgrowth Spectrum: A Mixed‐Methods Study to Understand Real‐World Experience With Alpelisib Treatment

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background PIK3CA‐related overgrowth spectrum (PROS) includes several rare overgrowth disorders resulting from somatic gain‐of‐function mutations in PIK3CA. Despite treatment advances, including the recent approval of alpelisib for PROS in the United States, literature detailing the patient experience with PROS is limited.
Vamsi Bollu, Kaitlin LaGasse, Cory D. Saucier, Kimberly Raymond, Miranda Lauher‐Charest, Lauren Crowder, Beilei Cai, Mary Lisha Paul, Denise Adams   +8 more
wiley   +1 more source

Activity profile of an FDA-approved compound library against Schistosoma mansoni [PDF]

, 2015
As plans to expand mass drug treatment campaigns to fight schistosomiasis form, worries about reliance on praziquantel as the sole available treatment motivate the investigation for novel antischistosomal compounds.
Gordana Panic, Ivan Scandale (349072), Jennifer Keiser, Gordana Panic (507685), Keiser, Jennifer, Mireille Vargas (392661), Scandale, Ivan, Jennifer Keiser (39606), Ivan Scandale, Vargas, Mireille, Panic, Gordana, Mireille Vargas   +11 more
core   +1 more source

Standardizing bioequivalence administration methods for chewable tablets: aligning product-specific guidance with current FDA recommendations

AAPS Open
This paper examines the standardization of bioequivalence (BE) administration methods for chewable tablets and other dosage forms instructing chewing in alignment for generic drug development.
Hye Lim Lim, Heather Boyce, Qi Zhang, Myong-Jin Kim, Wei-Jhe Sun   +4 more
doaj   +1 more source

Large-scale bioactivity analysis of the small-molecule assayed proteome.

PLoS ONE, 2017
This study presents an analysis of the small molecule bioactivity profiles across large quantities of diverse protein families represented in PubChem BioAssay.
Tyler William H Backman, Daniel S Evans, Thomas Girke   +2 more
doaj   +1 more source

2022 FDA TIDES (Peptides and Oligonucleotides) Harvest

Pharmaceuticals, 2023
A total of 37 new drug entities were approved in 2022; although that year registered the lowest number of drug approvals since 2016, the TIDES class consolidated its presence with a total of five authorizations (four peptides and one oligonucleotide ...
Othman Al Musaimi, Danah Al Shaer, Fernando Albericio, Beatriz G. de la Torre   +3 more
doaj   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source